Emergent BioSolutions (EBS) Short term Debt (2018 - 2020)
Historic Short term Debt for Emergent BioSolutions (EBS) over the last 8 years, with Q2 2020 value amounting to $22.3 million.
- Emergent BioSolutions' Short term Debt fell 5915.75% to $22.3 million in Q2 2020 from the same period last year, while for Jun 2020 it was $22.3 million, marking a year-over-year decrease of 5915.75%. This contributed to the annual value of $3.2 million for FY2019, which is 6831.68% down from last year.
- Per Emergent BioSolutions' latest filing, its Short term Debt stood at $22.3 million for Q2 2020, which was down 5915.75% from $3.2 million recorded in Q4 2019.
- Emergent BioSolutions' Short term Debt's 5-year high stood at $62.7 million during Q1 2019, with a 5-year trough of $3.2 million in Q4 2019.
- Over the past 3 years, Emergent BioSolutions' median Short term Debt value was $38.4 million (recorded in 2019), while the average stood at $34.8 million.
- As far as peak fluctuations go, Emergent BioSolutions' Short term Debt plummeted by 6831.68% in 2019, and later crashed by 5915.75% in 2020.
- Quarter analysis of 3 years shows Emergent BioSolutions' Short term Debt stood at $10.1 million in 2018, then tumbled by 68.32% to $3.2 million in 2019, then skyrocketed by 596.88% to $22.3 million in 2020.
- Its Short term Debt stands at $22.3 million for Q2 2020, versus $3.2 million for Q4 2019 and $55.7 million for Q3 2019.